DOT Affirms Stance on Medical Cannabis Drug Testing
The US Department of Transportation (DOT) has issued guidance affirming that commercially licensed drivers and other safety-sensitive transportation employees will continue to face sanctions for using state-authorized medical cannabis products. This directive, detailed in a memo dated May 26, 2026, clarifies that the Justice Department’s decision to reclassify medical cannabis from Schedule I to Schedule III of the Controlled Substances Act does not alter federal drug testing policies for these workers.
According to NORML’s report, the DOT memo explicitly states that “Marijuana use under state marijuana programs or other non-prescription sources does not qualify as a ‘legitimate medical explanation’ under 49 CFR § 40.137(a).” The regulation specifies that a legitimate medical explanation requires the use of a legally prescribed controlled substance in compliance with federal laws governing such a prescription. Even after rescheduling, state-dispensed medical cannabis does not constitute an FDA-approved drug, meaning state-issued medical marijuana cards or physician recommendations do not satisfy the requirements for a legitimate medical explanation under Part 40.
Regulatory Framework and Workforce Impact
The federal drug testing mandate applies to approximately six million private-sector safety-sensitive transportation workers. These regulations require commercially licensed drivers to undergo both pre-employment and random urinalysis testing for cannabis. This testing screens for the presence of the inert carboxy-THC metabolite, which can be detectable in urine for weeks or months following exposure, long after the acute psychoactive effects have dissipated, which typically occur within hours.
As previously reported by Hemp Gazette, the Department of Transportation has consistently maintained its stance on medical cannabis for safety-sensitive roles. The former Transportation Secretary testified before Congress in 2024 that rescheduling would not significantly change federal drug testing regulations, citing the 1988 drug testing regulations that mandate screening for cannabis regardless of its classification under the Controlled Substances Act.
Consequences for the Transportation Sector
- Over 139,000 truckers have tested positive for past cannabis exposure in recent years, a figure that surpasses the total number of failures for all other substances combined.
- A significant portion of these drivers have not reapplied for work in the industry, contributing to supply chain issues.
- Data published earlier in 2026 in the journal Drug and Alcohol Dependence Reports indicated no differences in next-day cognitive performance between cannabis consumers and abstainers.
Industry Perspectives and Policy Calls
The policy has drawn criticism from advocacy groups and industry stakeholders. Paul Armentano, NORML’s Deputy Director, stated in an op-ed in The Hill that “Suspicionless marijuana testing in the workplace is not now, nor has it ever been, an evidence-based policy.” He argued that current federal workplace drug testing policies should adapt to evolving marijuana laws and cease penalizing employees for off-hours activities that do not pose a workplace safety threat.
A survey conducted by the American Transportation Research Institute found that 62 percent of motor carrier company representatives believe that “changes were needed to federal drug policy rules in light of state-level legalization.” While DOT officials finalized a new rule in 2023 authorizing commercially licensed drivers the option to undergo oral fluid testing as an alternative to urinalysis, this policy change has not yet been implemented. NORML advocates for the expanded use of performance-based tests over presumptive detection of metabolites.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
